CER Daily Newsfeed

Report Stresses Value of Innovative Medicines to Patients and Society

(9/7, The Pharma Letter) reports “...One flaw pointed out with the ICER model is the assumption that a drug will always cost whatever its list price was during the first year it became available—and it only calculates value for patients that start taking it in that year. This disregards how drug prices fall over time, according to No Patient Left Behind.” Subscription Required

Differentiated Service Delivery Models Have Comparable Effectiveness to Standard of Care in HIV

(9/6, Julia Bonavitacola, The American Journal of Managed Care) reports “Differentiated service delivery (DSD) models were able to provide comparable effectiveness in treating people with HIV as the standard of care (SoC) when it came to maintaining care and viral suppression, according to a review published in Reviews in Medical Virology.” Full

AstraZeneca CEO Pascal Soriot Proposes a Novel Fix to the Drug Pricing Law's Alleged Cancer Problem

(9/6, Jason Mast, STAT Plus) reports “...On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution...[AstraZeneca CEO Pascal Soriot] said Congress could fix the issue by just changing when the countdown to drug negotiation begins. Instead of starting the 9- or 13- year clock when a drug is first approved, Medicare should start the clock once a drug loses its ‘orphan’ status - i.e. ‘once you get a new indication and treat more than 200,000 patients,’ Soriot said.” Subscription Required

Gilead-Backed Study Warns IRA Price Negotiations Could Hit R&D Harder Than Expected

(9/6, Nick Paul Taylor, Fierce Biotech) reports “...The U.S. Congressional Budget Office previously ran the numbers on the IRA, concluding that 15 out of 1,300 drugs would not come to market over the next 30 years. However, multiple analyses have called the CBO figures into question, with healthcare consulting firm Avalere, which received money from Gilead Sciences, finding the IRA could cut pharma revenues by $450 billion and another analysis suggesting between 24 and 49 currently available therapies wouldn't have reached the market if the pricing provisions took effect in 2014.” Full